Nab-paclitaxel:125mg/m2 intravenously administred on day 1,8 every 3 weeks Gemcitabine:1000mg/m2 intravenously administred on day 1,8 every 3 weeks

2 trials

Sponsors

Toho University Omori Medical Center

Conditions

Metastatic and Recurrenced Breast Cancermetastic and recurrance breast cancer

Phase 2

Phese 2 trial of weekly nab-paclitaxel in combination with gemcitabine in partients with metastatic breast cancer

RecruitingJPRN-UMIN000006427

Toho University Omori Medical Centermetastic and recurrance breast cancer

Start: 2011-04-01Target: 40Updated: 2026-06-29

Phese 2 trial of weekly nab-paclitaxel in combination with gemcitabine in patients with metastatic breast cancer who have failed prior chemotherapy

RecruitingJPRN-UMIN000009153

Toho University Omori Medical CenterMetastatic and Recurrenced Breast Cancer

Start: 2012-09-01Target: 20Updated: 2026-06-29